Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck

Molecular Carcinogenesis

Volumn 18, Issue 2, 1997, Pages 78-88

  Cardinali, Massimo ^a   Kratochvil, F James ^b,d   Ensley, John F ^c   Robbins, Keith C ^a   Yeudall, W Andrew ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e MSC 4330 ^*  (United States)

Author keywords

Angiogenesis; Cell transformation; Metastasis; p53; Squamous cell carcinoma; Tumor suppressor

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

3T3 CELLS; ANIMALS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLASMIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030932669     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199702)18:2<78::AID-MC3>3.0.CO;2-M     Document Type: Article

References (70)

1. Levine AJ. The tumor suppressor genes. Annu Rev Biochem 62:623-651, 1993.
2. Gusterson BA, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6:1785-1789, 1991.
3. Brachman DG, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52:4832-4836, 1992.
4. Sakai E, Rikimaru K, Ueda M, et al. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 52:867-872, 1992.
5. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 52:5997-6000, 1992.
6. Burns JE, Baird MC, Clark LJ, et al. Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer 67:1274-1284, 1993.
7. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993.
8. Min B-M, Baek J-H, Shin K-H, Gujuluva CN, Cherrick HM, Park N-H. Inactivation of the p53 gene by either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur J Cancer B Oral Oncol 30B:338-345, 1994.
9. Yeudall WA, Paterson IC, Patel V, Prime SS. Presence of human papillomavirus sequences in tumor-derived human oral keratinocytes expressing mutant p53. Eur J Cancer B Oral Oncol 31B:136-143, 1995.
10. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711, 1991.
11. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
12. Funk WD, Pak DT, Kara RH, Wright WE, Shay JW. A transcriptionally active DNA binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871, 1992.
13. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992.
14. Bargonetti J, Reynisdottir I, Friedman P, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6:1886-1898, 1992.
15. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993.
16. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
17. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13:4816-4822, 1994.
18. Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11:12-19, 1991.
19. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12:5581-5592, 1992.
20. Sturzbecher H-W, Brain R, Addison C, et al. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1543-1523, 1992.
21. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7:2556-2564, 1993.
22. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456, 1991.
23. Harris CC. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981, 1993.
24. Wang P, Reed M, Wang Y, et al. p53 domains: Structure, oligomerization and transformation. Mol Cell Biol 14:5182-5191, 1994.
25. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotem is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991.
26. Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105:607-612, 1993.
27. Raycroft L, Wu H, Lozano G. Transcription activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990.
28. Farmer GE, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 358:83-86, 1992.
29. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-832, 1992.
30. Unger T, Nau MM, Segal S, Minna JD. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11:1383-1390, 1992.
31. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8:2159-2166, 1993.
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
33. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-431, 1991.
34. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216-4220, 1993.
35. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989.
36. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767, 1989.
37. Chen P-L, Chen Y, Bookstein R, Lee W-H. Genetic mechanism of tumor suppression by the human p53 gene. Science 250:1576-1580, 1990.
38. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992.
39. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of cellular tumor antigen in transformation of normal embryonic cells. Nature 312:646-649, 1984.
40. Kikuchi-Yanoshita R, Tanaka K, Muraoka M, et al. Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene. Oncogene 11:1339-1345, 1995.
41. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555, 1994.
42. Macfarlane GJ, Zheng T, Marshall JR, et al. Alcohol, tobacco, diet and the risk of oral cancer: A pooled analysis of three case-control studies. Eur J Cancer B Oral Oncol 31B:181-187, 1995.
43. Cardinali M, Pietraskiewicz H, Ensley JF, Robbins KC. Tyrosine phosphorylation as a marker for aberrantly regulated growth promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer 61:98-103, 1995.
44. Rheinwald JG, Beckett MA. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 41:1657-1663, 1981.
45. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15:2683-2686, 1994.
46. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, Chasin L. DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci USA 76:1373-1376, 1979.
47. Michaelovitz D, Halevy O, Oren M. p53 mutations: Gains or losses? J Cell Biochem 45:22-29, 1991.
48. 47A. Yeudall WA, Jakus J, Ensley JF, Robbins KC. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog 18:89-96, 1997.
49. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54:321-326, 1994.
50. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079-6082, 1992.
51. Tominaga O, Hamelin R, Trouvat V, et al. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 8:2653-2658, 1993.
52. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
53. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
54. Smith ML, Chen I-T, Zhan Q, O'Connor PM, Fornace AJ. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10:1053-1059, 1995.
55. Peacock JW, Chung S, Bristow RG, Hill RP, Benchimol S. The p53-mediated G1 checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ-ras. Mol Cell Biol 15:1446-1454, 1995.
56. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16:1126-1137, 1996.
57. Lane DP. p53, guardian of the genome. Nature 358:15-16, 1992.
58. Srivastava S, Lou Z, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990.
59. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994.
60. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 92:6788-6792, 1995.
61. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial cell growth factor expression. Oncogene 9:963-969, 1994.
62. Sharkey FE, Fogh J. Metastasis of human tumors in athymic nude mice. Int J Cancer 24:733-738, 1979.
63. Thompson TC, Park SH, Timme TL, et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10:869-879, 1995.
64. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. p53 and erbB2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch 423:329-334, 1993.
65. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
66. Hughes JH, Cohen MB, Robinson RA. p53 immunoreactivity in primary and metastatic prostate adenocarcinoma. Mod Pathol 8:462-466, 1995.
67. Kastrinakis WV, Ramchurren N, Rieger KM, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647-652, 1995.
68. Kim JH, Takahashi T, Chiba I, et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 83:938-943, 1991.
69. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: A late event? Oncogene 6:1685-1690, 1991.
70. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 51:5976-5979, 1991.